NASDAQ:RANI • US7530181004
Past quarterly earnings results for RANI THERAPEUTICS HOLDINGS-A (RANI), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.12 | -0.13 | 4.61% | 50.00% | - | - | ||
| Q2 2025 | -0.18 | -0.20 | 9.50% | 30.77% | - | - | ||
| Q1 2025 | -0.22 | -0.21 | -6.08% | 24.14% | 172K | - | - | |
| Q4 2024 | -0.27 | -0.25 | -7.31% | - | 1.028M | - | - | |
| Q3 2024 | -0.24 | -0.26 | 8.50% | 33.33% | - | - | ||
| Q2 2024 | -0.26 | -0.32 | 18.43% | 29.73% | - | - | ||
| Q1 2024 | -0.29 | -0.21 | -35.39% | 12.12% | - | - | ||
| Q4 2023 | -0.27 | -0.32 | 15.05% | 22.86% | - | - | ||
| Q3 2023 | -0.36 | -0.37 | 3.48% | -9.09% | - | - | ||
| Q2 2023 | -0.37 | -0.41 | 10.28% | -19.35% | - | - | ||
| Q1 2023 | -0.33 | -0.42 | 21.76% | -13.79% | - | - | ||
| Q4 2022 | -0.35 | -0.35 | 1.40% | -29.63% | 110.497K | -100.00% | - | |
| Q3 2022 | -0.33 | -0.48 | 30.87% | -175.00% | 132.6K | -100.00% | - | |
| Q2 2022 | -0.31 | -0.59 | 47.37% | -158.33% | 132.6K | -100.00% | -100.00% | |
| Q1 2022 | -0.29 | -0.67 | 56.92% | - | 331.5K | -100.00% | -100.00% | |
| Q4 2021 | -0.27 | -0.50 | 46.52% | - | 165.75K | -100.00% | -100.00% | |
| Q3 2021 | -0.12 | -0.18 | 34.64% | - | 293.25K | -100.00% | -100.00% | |
| Q2 2021 | -0.12 | -0.18 | 33.16% | - | 1.96M | 499.8K | 292.16% | 3,166.67% |
| Q1 2021 | - | - | 760K | - | 850.00% | |||
| Q4 2020 | - | - | 210K | - | - | |||
| Q3 2020 | - | - | 110K | - | - | |||
| Q2 2020 | - | - | 60K | - | - | |||
| Q1 2020 | - | - | 80K | - | - |
Notes
RANI THERAPEUTICS HOLDINGS-A (RANI) last reported earnings on 11/6/2025.
RANI THERAPEUTICS HOLDINGS-A (RANI) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, RANI THERAPEUTICS HOLDINGS-A (RANI) has beaten EPS estimates in 2 out of 4 releases.